Asie · Bourse & Finance · The Investor

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

Publié par The Investor · Corée du Sud il y a 22 h

Hanmi Pharmaceutical’s Eppe is poised to challenge Wegovy and Mounjaro in Korea’s fast-growing obesity drug market, with price emerging as a potentially decisiv ...

Lire l'article complet sur The Investor Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.theinvestor.co.kr)

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

À lire aussi

Best bank stock to buy amid Q2 business updates: PNB, Canara, Union Bank, Indian Bank or Bandhan? Target Prices

Hao Mart owner resisting OG’s mortgage foreclosure on his GCB

Nifty Outlook for October 6: Will bears use index bounce as a selling opportunity on weekly expiry?

TVS ASL raises ₹425 crore from Crescent Enterprises in Series D round

Is joining EPS a must at Rs 25K+ salary?

ภาวะตลาดอนุพันธ์:แกว่งผันผวน แม้คลายกังวลเฟดอาจเลื่อนขึ้นดอกเบี้ย แต่ผลน้ำท่วมยังกดดัน

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

Partager

À lire aussi

Best bank stock to buy amid Q2 business updates: PNB, Canara, Union Bank, Indian Bank or Bandhan? Target Prices

Hao Mart owner resisting OG’s mortgage foreclosure on his GCB

Nifty Outlook for October 6: Will bears use index bounce as a selling opportunity on weekly expiry?

TVS ASL raises ₹425 crore from Crescent Enterprises in Series D round

Is joining EPS a must at Rs 25K+ salary?

ภาวะตลาดอนุพันธ์:แกว่งผันผวน แม้คลายกังวลเฟดอาจเลื่อนขึ้นดอกเบี้ย แต่ผลน้ำท่วมยังกดดัน